FDA warning letter · Drugs

Chengdu Brilliant Biopharmaceutical Co., Ltd.

Issued · Posted by FDA

Selected passages from the FDA letter

Quoted FDA text from the published dataset. These selected excerpts are not the complete letter.

Passage 1

Failure to demonstrate that your manufacturing process can reproducibly manufacture an API meeting its predetermined quality attributes.

Passage 2

Failure to test the identity of each batch of incoming production material.